PTGX Q4 2017 Earnings — Protagonist Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

PTGXProtagonist Therapeutics, Inc.

$6B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$11M100.0% margin

Operating Income

-$4M-31.1% margin

Net Income

-$3M-27.1% margin

EPS (Diluted)

$-0.15

QoQ Revenue Growth

+28.5%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$164M

Total Liabilities

$43M

Stockholders' Equity

-$102M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$11M	$0	—
Operating Income	-$4M	-$11M	+69.2%
Net Income	-$3M	-$11M	+72.9%